SERB Pharmaceuticals, a global specialty pharmaceutical company focused on rare diseases and medical emergencies, today announced the successful completion of its acquisition of Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer.
Health Technology Insights: CatalYm Updates Leadership to Boost Visugromab Trials
“We are excited to welcome Y-mAbs into SERB. The acquisition strengthens our Rare Oncology portfolio with the addition of Danyelza (naxitamab-gqgk) and brings deep oncology expertise that will help us to expand our partnerships with the US oncology community and to advance treatments for rare and hard-to-treat cancers”, said Vanessa Wolfeler, Chief Executive Officer of SERB. “This marks a significant step forward in delivering on SERB’s growth strategy and vision, but more importantly, it allows us to help more children and families facing pediatric cancers.”
Completion of Tender Offer and Transaction Details
The tender offer period, initiated on August 18, 2025, expired at one minute following 11:59 p.m., Eastern Time, on September 15, 2025. The conditions of the tender offer having been satisfied, SERB has accepted all such tendered shares for $8.60 per share, and following a statutory merger under Section 251(h) of the Delaware General Corporation Law on September 16, 2025, Y-mAbs became a wholly owned subsidiary of SERB and was delisted from the Nasdaq Global Select Market. All remaining Y-mAbs shares that were not tendered in the tender offer will be converted into the right to receive the same $8.60 per share in cash paid for shares that were tendered in the tender offer.
Health Technology Insights: Raludotatug Deruxtecan Gets FDA Breakthrough for Ovarian Cancer
About Danyelza (naxitamab-gqgk)
Danyelza (naxitamab-gqgk) is indicated, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), for the treatment of pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication was approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory trial. Danyelza includes a Boxed Warning for serious infusion-related reactions, such as cardiac arrest and anaphylaxis, and neurotoxicity, such as severe neuropathic pain and transverse myelitis.
Danyelza is currently not approved for the treatment of osteosarcoma in any jurisdiction.
Health Technology Insights: Hercules Pharmaceuticals Appoints Elie Bahou as Executive Vice President
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – GlobeNewswire
